Johnson & Johnson (J&J) has outlined a new review of its strategies in the drug development market, a move that will have implications for its staff in pharmaceutical jobs.
The company is aiming to initiate a number of new measures to increase its share of the global healthcare market, with its pharmaceutical division currently ranking as the eighth largest in the world.
Investment in talent will play a key role in this, allowing it to expand research and development capacity in emerging markets and new fields, as well as placing able staff in key leadership roles.
Other measures will include a greater focus on differentiated medicine and further development of its transformational pipeline, as well as expansion of its geographic presence.
Vice-chairman of J&J's executive committee Sheri McCoy said: "We are well-positioned for the new demands, requirements, demographics and trends shaping the healthcare market."
In the first quarter of 2011, the company generated $16.2 billion (£9.82 billion) in sales, with $6.1 billion of this total coming from its pharmaceutical division.